Y mAbs Therapeutics (NASDAQ:YMAB) — Market Cap & Net Worth
Market Cap & Net Worth: Y mAbs Therapeutics (YMAB)
Y mAbs Therapeutics (NASDAQ:YMAB) has a market capitalization of $391.22 Million ($391.22 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13671 globally and #3239 in its home market, demonstrating a 0.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Y mAbs Therapeutics's stock price $8.61 by its total outstanding shares 45438400 (45.44 Million). Review how much debt does Y mAbs Therapeutics carry to assess the company's total debt and financial obligations.
Y mAbs Therapeutics Market Cap History: 2018 to 2025
Y mAbs Therapeutics's market capitalization history from 2018 to 2025. Data shows change from $924.22 Million to $391.22 Million (-13.64% CAGR).
Index Memberships
Y mAbs Therapeutics is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.02% | #367 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1321 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.02% | #197 of 263 |
Weight: Y mAbs Therapeutics's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Y mAbs Therapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Y mAbs Therapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.06x
Y mAbs Therapeutics's market cap is 4.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.25 Billion | $20.75 Million | -$119.34 Million | 108.42x | N/A |
| 2021 | $736.56 Million | $34.90 Million | -$56.34 Million | 21.11x | N/A |
| 2022 | $221.74 Million | $65.27 Million | -$96.33 Million | 3.40x | N/A |
| 2023 | $309.89 Million | $84.82 Million | -$21.43 Million | 3.65x | N/A |
| 2024 | $355.78 Million | $87.69 Million | -$29.67 Million | 4.06x | N/A |
Competitor Companies of YMAB by Market Capitalization
Companies near Y mAbs Therapeutics in the global market cap rankings as of June 19, 2026.
Key companies related to Y mAbs Therapeutics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Y mAbs Therapeutics Historical Marketcap From 2018 to 2025
Between 2018 and today, Y mAbs Therapeutics's market cap moved from $924.22 Million to $ 391.22 Million, with a yearly change of -13.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $391.22 Million | +9.96% |
| 2024 | $355.78 Million | +14.81% |
| 2023 | $309.89 Million | +39.75% |
| 2022 | $221.74 Million | -69.90% |
| 2021 | $736.56 Million | -67.26% |
| 2020 | $2.25 Billion | +58.43% |
| 2019 | $1.42 Billion | +53.64% |
| 2018 | $924.22 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Y mAbs Therapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $391.22 Million USD |
| MoneyControl | $391.22 Million USD |
| MarketWatch | $391.22 Million USD |
| marketcap.company | $391.22 Million USD |
| Reuters | $391.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Y mAbs Therapeutics
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-ri… Read more